Acumen Pharmaceuticals (ABOS) Competitors $1.40 +0.10 (+7.25%) As of 01:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABOS vs. OCGN, TKNO, TRDA, CRVS, PVLA, TSVT, TNXP, ALLO, INZY, and ALDXShould you be buying Acumen Pharmaceuticals stock or one of its competitors? The main competitors of Acumen Pharmaceuticals include Ocugen (OCGN), Alpha Teknova (TKNO), Entrada Therapeutics (TRDA), Corvus Pharmaceuticals (CRVS), Palvella Therapeutics (PVLA), 2seventy bio (TSVT), Tonix Pharmaceuticals (TNXP), Allogene Therapeutics (ALLO), Inozyme Pharma (INZY), and Aldeyra Therapeutics (ALDX). These companies are all part of the "pharmaceutical products" industry. Acumen Pharmaceuticals vs. Its Competitors Ocugen Alpha Teknova Entrada Therapeutics Corvus Pharmaceuticals Palvella Therapeutics 2seventy bio Tonix Pharmaceuticals Allogene Therapeutics Inozyme Pharma Aldeyra Therapeutics Ocugen (NASDAQ:OCGN) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability. Is OCGN or ABOS more profitable? Acumen Pharmaceuticals has a net margin of 0.00% compared to Ocugen's net margin of -1,271.12%. Acumen Pharmaceuticals' return on equity of -58.24% beat Ocugen's return on equity.Company Net Margins Return on Equity Return on Assets Ocugen-1,271.12% -223.00% -92.20% Acumen Pharmaceuticals N/A -58.24%-46.53% Do insiders & institutionals have more ownership in OCGN or ABOS? 10.3% of Ocugen shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 4.3% of Ocugen shares are owned by insiders. Comparatively, 7.1% of Acumen Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, OCGN or ABOS? Ocugen has a beta of 4.18, meaning that its stock price is 318% more volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Which has better earnings & valuation, OCGN or ABOS? Ocugen has higher revenue and earnings than Acumen Pharmaceuticals. Ocugen is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcugen$4.05M75.35-$54.05M-$0.19-5.50Acumen PharmaceuticalsN/AN/A-$102.33M-$1.94-0.72 Do analysts recommend OCGN or ABOS? Ocugen currently has a consensus target price of $6.00, indicating a potential upside of 474.16%. Acumen Pharmaceuticals has a consensus target price of $6.33, indicating a potential upside of 350.77%. Given Ocugen's higher probable upside, analysts clearly believe Ocugen is more favorable than Acumen Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocugen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Acumen Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to OCGN or ABOS? In the previous week, Acumen Pharmaceuticals had 4 more articles in the media than Ocugen. MarketBeat recorded 5 mentions for Acumen Pharmaceuticals and 1 mentions for Ocugen. Ocugen's average media sentiment score of 1.87 beat Acumen Pharmaceuticals' score of 0.61 indicating that Ocugen is being referred to more favorably in the media. Company Overall Sentiment Ocugen Very Positive Acumen Pharmaceuticals Positive SummaryAcumen Pharmaceuticals beats Ocugen on 7 of the 13 factors compared between the two stocks. Get Acumen Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABOS vs. The Competition Export to ExcelMetricAcumen PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$85.10M$2.92B$5.56B$9.30BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-0.7220.3528.6119.64Price / SalesN/A304.32437.49188.30Price / CashN/A43.1536.0257.93Price / Book0.467.718.185.63Net Income-$102.33M-$55.11M$3.23B$257.73M7 Day Performance12.40%0.68%-0.25%0.07%1 Month Performance23.25%8.22%5.40%8.32%1 Year Performance-55.40%-2.64%26.35%13.78% Acumen Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABOSAcumen Pharmaceuticals3.0011 of 5 stars$1.41+7.3%$6.33+350.8%-54.7%$85.10MN/A-0.7220News CoverageOCGNOcugen1.371 of 5 stars$0.97+1.4%$6.00+518.6%-44.0%$279.47M$4.05M-5.1180Positive NewsTKNOAlpha Teknova2.0293 of 5 stars$4.99-4.2%$8.50+70.3%+243.8%$278.43M$37.74M-10.40240Positive NewsTRDAEntrada Therapeutics3.3079 of 5 stars$6.97-3.6%$25.67+268.2%-64.3%$274.40M$172.22M8.61110CRVSCorvus Pharmaceuticals2.8334 of 5 stars$3.90-1.3%$15.00+284.6%+108.5%$269.27MN/A-3.9830Positive NewsPVLAPalvella Therapeutics2.5116 of 5 stars$24.90+3.2%$46.29+85.9%N/A$266.66M$42.81M-2.06N/ATSVT2seventy bioN/A$5.00flat$5.00N/A$266.15M$48.37M-2.69440TNXPTonix Pharmaceuticals2.6659 of 5 stars$35.44-0.1%$585.00+1,550.7%-25.9%$261.03M$10.09M-0.0250Gap UpALLOAllogene Therapeutics3.6379 of 5 stars$1.16-2.5%$8.44+628.0%-58.4%$260.29M$20K-0.94310Positive NewsINZYInozyme Pharma3.4856 of 5 stars$4.00flat$11.75+193.8%N/A$258.25MN/A-2.3750Positive NewsALDXAldeyra Therapeutics2.5714 of 5 stars$4.35+1.2%$9.50+118.4%+25.5%$257.55MN/A-4.4810News CoveragePositive News Related Companies and Tools Related Companies OCGN Competitors TKNO Competitors TRDA Competitors CRVS Competitors PVLA Competitors TSVT Competitors TNXP Competitors ALLO Competitors INZY Competitors ALDX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABOS) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acumen Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
